QGEN vs. TEVA, BGNE, RDY, CTLT, ROIV, LNTH, RVMD, SMMT, ELAN, and KRYS
Should you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), Summit Therapeutics (SMMT), Elanco Animal Health (ELAN), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.
Teva Pharmaceutical Industries (NYSE:TEVA) and Qiagen (NYSE:QGEN) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation, profitability and community ranking.
Qiagen has a net margin of 17.38% compared to Qiagen's net margin of -2.88%. Qiagen's return on equity of 37.33% beat Teva Pharmaceutical Industries' return on equity.
In the previous week, Teva Pharmaceutical Industries had 16 more articles in the media than Qiagen. MarketBeat recorded 19 mentions for Teva Pharmaceutical Industries and 3 mentions for Qiagen. Teva Pharmaceutical Industries' average media sentiment score of 0.91 beat Qiagen's score of 0.74 indicating that Qiagen is being referred to more favorably in the news media.
Teva Pharmaceutical Industries received 1071 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 67.69% of users gave Teva Pharmaceutical Industries an outperform vote while only 60.99% of users gave Qiagen an outperform vote.
Qiagen has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Teva Pharmaceutical Industries presently has a consensus target price of $18.56, indicating a potential upside of 8.48%. Qiagen has a consensus target price of $51.05, indicating a potential upside of 16.24%. Given Teva Pharmaceutical Industries' higher probable upside, analysts plainly believe Qiagen is more favorable than Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.
Summary
Qiagen beats Teva Pharmaceutical Industries on 10 of the 18 factors compared between the two stocks.
Get Qiagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
